LOXL3 and neoplasm: To evaluate treatment response in metastatic colorectal cancer (mCRC), a study proposed combining Zinc Finger E-Box Binding Homeobox 2 (ZEB2) and LOXL3 as circulating tumor cell (CTC)-based indicators of EMT (Insua et al., 2017).